Ernexa Therapeutics Inc. (ERNA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cell therapies for cancer and autoimmune diseases. The company operates as a non-accelerated filer and a smaller reporting company. As of May 8, 2026, there were 1,166,333 shares of common stock outstanding. All share data in this report reflects a 1-for-25 reverse stock split effected on May 4, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5.5) million | $(8.2) million |
| Operating Expenses | $5.6 million | $2.7 million |
| Cash and Cash Equivalents (End of Period) | $9.2 million | $1.9 million |
| Net Cash Used in Operating Activities | $(2.3) million | $(2.1) million |
| Net Cash Provided by Financing Activities | $9.6 million | $2.3 million |
| Accumulated Deficit | $(251.1) million | $(239.7) million |
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by $2.7 million compared to Q1 2025, primarily due to the absence of a $5.3 million non-cash forward sales contract expense recognized in the prior year.
- Goodwill Impairment: The company recognized a non-cash impairment charge of $2.0 million related to goodwill from a 2018 acquisition, as the fair value of the reporting unit was determined to be less than its carrying value.
- Operating Expenses: Total operating expenses increased by $2.9 million. Research and Development (R&D) expenses rose by $0.6 million due to increased study fees for the lead candidate ERNA-101 and higher payroll. General and Administrative (G&A) expenses increased by $0.2 million, driven by accrued bonuses and professional fees, partially offset by lower stock-based compensation.
- Liquidity Position: Cash balances increased significantly from $1.9 million to $9.2 million, driven by a public offering in February 2026 that generated approximately $9.5 million in net proceeds.
Guidance, Outlook, and Risks
- Capital Resources: As of April 30, 2026, cash was approximately $8.3 million, which management states is insufficient to fund operations for the next twelve months without additional capital. The company expects to utilize its At-the-Market (ATM) program, established under a Universal Shelf registration, to cover shortfalls.
- Development Milestones: The company expects to complete IND-enabling studies and submit an Investigational New Drug (IND) application in 2026, with a Phase 1 investigator-sponsored clinical trial anticipated in the second half of 2026.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's $1.00 minimum bid price rule. Following a 1-for-25 reverse stock split on May 4, 2026, the company expects to regain compliance by May 15, 2026. Failure to maintain compliance could result in delisting.
- Going Concern: While the company has raised capital, it continues to incur losses and has an accumulated deficit of $251.1 million. Continued access to capital markets is critical for its survival.
Investor Verification Checklist
- Verify the status of the Nasdaq compliance extension and whether the stock price has maintained the $1.00 minimum bid price for the required 10 consecutive business days.
- Confirm the timeline for the IND submission and the initiation of the Phase 1 clinical trial for ERNA-101.
- Monitor the utilization of the $9.2 million ATM program and any subsequent equity issuances that may cause dilution.
- Review the details of the contingent consideration liability ($41,000) related to the 2023 asset acquisition, which expires in April 2026.
- Assess the impact of the $2.0 million goodwill impairment on future valuation and potential asset write-downs.